Small Molecules to Regulate the GH/IGF1 Axis by Inhibiting the Growth Hormone Receptor Synthesis

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2022 Aug 15

PMID 35966052

Authors

Lieke M van der Velden

Peter Maas

Miranda van Amersfoort

Elpetra P M Timmermans-Sprang

Anneloes Mensinga

Elisabeth van der Vaart

Fabrice Malergue

Henk Vietor

Patrick W B Derksen

Judith Klumperman

Andreas van Agthoven

David A Egan

Jan A Mol

Ger J Strous

Affiliations

Soon will be listed here.

Abstract

Growth hormone (GH) and insulin-like growth factor-1 (IGF1) play an important role in mammalian development, cell proliferation and lifespan. Especially in cases of tumor growth there is an urgent need to control the GH/IGF1 axis. In this study we screened a 38,480-compound library, and in two consecutive rounds of analogues selection, we identified active lead compounds based on the following criteria: inhibition the GH receptor (GHR) activity and its downstream effectors Jak2 and STAT5, and inhibition of growth of breast and colon cancer cells. The most active small molecule (BM001) inhibited both the GH/IGF1 axis and cell proliferation with an IC50 of 10-30 nM of human cancer cells. BM001 depleted GHR in human lymphoblasts. In preclinical xenografted experiments, BM001 showed a strong decrease in tumor volume in mice transplanted with MDA-MB-231 breast cancer cells. Mechanistically, the drug acts on the synthesis of the GHR. Our findings open the possibility to inhibit the GH/IGF1 axis with a small molecule.

Citing Articles

In Vivo Effects of a GHR Synthesis Inhibitor During Prolonged Treatment in Dogs.

Timmermans E, Blankevoort J, Grinwis G, Mesu S, Gehring R, Delhanty P Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39459020 PMC: 11510805. DOI: 10.3390/ph17101381.

Ghrelin regulating liver activity and its potential effects on liver fibrosis and .

Zhu J, Zhou T, Menggen M, Aimulajiang K, Wen H Front Cell Infect Microbiol. 2024; 13:1324134.

PMID: 38259969 PMC: 10800934. DOI: 10.3389/fcimb.2023.1324134.

Construction of a high-density genetic linkage map and QTL mapping of growth and cold tolerance traits in Takifugu fasciatus.

Zhang Y, Li J, Chu P, Shang R, Yin S, Wang T BMC Genomics. 2023; 24(1):645.

PMID: 37891474 PMC: 10604518. DOI: 10.1186/s12864-023-09740-4.

WIP1 is a novel specific target for growth hormone action.

Apaydin T, Zonis S, Zhou C, Valencia C, Barrett R, Strous G iScience. 2023; 26(11):108117.

PMID: 37876819 PMC: 10590974. DOI: 10.1016/j.isci.2023.108117.

A novel antifolate suppresses growth of FPGS-deficient cells and overcomes methotrexate resistance.

van der Krift F, Zijlmans D, Shukla R, Javed A, Koukos P, Schwarz L Life Sci Alliance. 2023; 6(11).

PMID: 37591722 PMC: 10435995. DOI: 10.26508/lsa.202302058.

References

Buchman M, Bell S, Kopchick J . Growth Hormone Discovery and Structure. Pediatr Endocrinol Rev. 2018; 16(Suppl 1):2-10. DOI: 10.17458/per.vol16.2018.bbk.ghdiscoverystructure. View

Strous G, van Kerkhof P, Govers R, Ciechanover A, Schwartz A . The ubiquitin conjugation system is required for ligand-induced endocytosis and degradation of the growth hormone receptor. EMBO J. 1996; 15(15):3806-12. PMC: 452061. View

Laron Z . LESSONS FROM 50 YEARS OF STUDY OF LARON SYNDROME. Endocr Pract. 2015; 21(12):1395-402. DOI: 10.4158/EP15939.RA. View

Basu R, Qian Y, Kopchick J . MECHANISMS IN ENDOCRINOLOGY: Lessons from growth hormone receptor gene-disrupted mice: are there benefits of endocrine defects?. Eur J Endocrinol. 2018; 178(5):R155-R181. DOI: 10.1530/EJE-18-0018. View

da Silva Almeida A, Strous G, van Rossum A . βTrCP controls GH receptor degradation via two different motifs. Mol Endocrinol. 2011; 26(1):165-77. PMC: 5417165. DOI: 10.1210/me.2011-1211. View

Basu R, Nahar K, Kulkarni P, Kerekes O, Sattler M, Hall Z . A novel peptide antagonist of the human growth hormone receptor. J Biol Chem. 2021; 296:100588. PMC: 8086144. DOI: 10.1016/j.jbc.2021.100588. View

Cendrowski J, Maminska A, Miaczynska M . Endocytic regulation of cytokine receptor signaling. Cytokine Growth Factor Rev. 2016; 32:63-73. DOI: 10.1016/j.cytogfr.2016.07.002. View

Nespital T, van der Velden L, Mensinga A, van der Vaart E, Strous G . Fos-Zippered GH Receptor Cytosolic Tails Act as Jak2 Substrates and Signal Transducers. Mol Endocrinol. 2016; 30(3):290-301. PMC: 5414649. DOI: 10.1210/me.2015-1315. View

van Garderen E, van der Poel H, Swennenhuis J, Wissink E, Rutteman G, Hellmen E . Expression and molecular characterization of the growth hormone receptor in canine mammary tissue and mammary tumors. Endocrinology. 1999; 140(12):5907-14. DOI: 10.1210/endo.140.12.7189. View

10.

Zhao C, Cai S, Shin K, Lim A, Kalisky T, Lu W . Stromal activity coordinates a niche signaling program for mammary epithelial stem cells. Science. 2017; 356(6335). DOI: 10.1126/science.aal3485. View

11.

Kopchick J, Parkinson C, Stevens E, Trainer P . Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev. 2002; 23(5):623-46. DOI: 10.1210/er.2001-0022. View

12.

Trainer P, Drake W, Katznelson L, Freda P, Lely A, Dimaraki E . Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000; 342(16):1171-7. DOI: 10.1056/NEJM200004203421604. View

13.

Brittain A, Basu R, Qian Y, Kopchick J . Growth Hormone and the Epithelial-to-Mesenchymal Transition. J Clin Endocrinol Metab. 2017; 102(10):3662-3673. DOI: 10.1210/jc.2017-01000. View

14.

Amit T, Hartmann K, Shoshany G, Baruch Y, Youdim M, Hochberg Z . The turnover of growth hormone (GH)-binding protein and GH receptor in rabbit and rat. Mol Cell Endocrinol. 1993; 94(2):149-54. DOI: 10.1016/0303-7207(93)90163-e. View

15.

van Kerkhof P, Govers R, Alves dos Santos C, Strous G . Endocytosis and degradation of the growth hormone receptor are proteasome-dependent. J Biol Chem. 2000; 275(3):1575-80. DOI: 10.1074/jbc.275.3.1575. View

16.

Ivanova I, Vermeulen J, Ercan C, Houthuijzen J, Saig F, Vlug E . FER kinase promotes breast cancer metastasis by regulating α6- and β1-integrin-dependent cell adhesion and anoikis resistance. Oncogene. 2013; 32(50):5582-92. PMC: 3898493. DOI: 10.1038/onc.2013.277. View

17.

Fu N, Rios A, Pal B, Law C, Jamieson P, Liu R . Identification of quiescent and spatially restricted mammary stem cells that are hormone responsive. Nat Cell Biol. 2017; 19(3):164-176. DOI: 10.1038/ncb3471. View

18.

Groner B, von Manstein V . Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition. Mol Cell Endocrinol. 2017; 451:1-14. DOI: 10.1016/j.mce.2017.05.033. View

19.

Zhou Y, Xu B, Maheshwari H, He L, Reed M, Lozykowski M . A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc Natl Acad Sci U S A. 1997; 94(24):13215-20. PMC: 24289. DOI: 10.1073/pnas.94.24.13215. View

20.

Brooks A, Dai W, OMara M, Abankwa D, Chhabra Y, Pelekanos R . Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science. 2014; 344(6185):1249783. DOI: 10.1126/science.1249783. View